Pharmacoecon Open. 2021 Jun;5(2):197-209. doi: 10.1007/s41669-020-00236-5. Epub 2020 Nov 09.
Minimally Invasive Sacroiliac Joint Fusion with Triangular Titanium Implants: Cost-Utility Analysis from NHS Perspective.
PharmacoEconomics - open
Deirdre B Blissett, Rob S Blissett, Matthew P Newton Ede, Philip M Stott, Daniel J Cher, W Carlton Reckling
Affiliations
Affiliations
- MedTech Economics Ltd., Winchester, UK. [email protected].
- MedTech Economics Ltd., Winchester, UK.
- The Royal Orthopaedic Hospital, Bristol Road South, Birmingham, UK.
- Precision Spine, 81 Harborne Road, Edgbaston, Birmingham, UK.
- Brighton and Sussex University Hospitals NHS Trust, Eastern Road, Brighton, UK.
- Department of Clinical Affairs, SI-BONE, Inc., San Jose, CA, USA.
- Department of Medical Affairs, SI-BONE, Inc., San Jose, CA, USA.
PMID: 33165824
PMCID: PMC8160075 DOI: 10.1007/s41669-020-00236-5
Abstract
OBJECTIVE: The aim was to identify the cost-effectiveness of minimally invasive sacroiliac joint fusion (MI SIJF) surgery with titanium triangular implants for patients with sacroiliac joint (SIJ) pain who have failed conservative management, compared to non-surgical management (NSM) from a National Health Service (NHS) England perspective.
METHODS: Over a time horizon of 5 years, a cohort state transition model compared the costs and outcomes of treating patients with MI SIJF to those of traditional NSM treatment pathways. The NSM arm included two treatments: grouped physical therapy and corticosteroid injections (PTSI) or radiofrequency ablation (RFA). Three different strategies were considered: (1) a stepped pathway, (2) patients split between PTSI and RFA, and (3) RFA only. The outcome measure was incremental cost-effectiveness ratio (ICER), reported in 2018 British pounds per quality-adjusted life year (QALY) gained. One-way and probabilistic sensitivity analyses were used to test the robustness of the model results.
RESULTS: Patients undergoing MI SIJF accrued total procedure-related and pain-management costs of £8358, while NSM treatment strategy 1 had total costs of £6880. The MI SIJF cohort had 2.98 QALYs compared to strategy 1 with 2.30 QALYs. This resulted in an ICER for MI SIJF versus strategy 1 of £2164/QALY gained. Strategy 2 of the NSM arm had lower costs than strategy 1 (£6564) and 2.26 QALYs, and this resulted in an ICER of £2468/QALY gained for MI SIJF. Strategy 3 of the NSM arm had lower costs than strategy 1 (£6580), and this resulted in 2.28 QALYs and an ICER of £2518/QALY gained for MI SIJF. Probabilistic sensitivity analysis shows that at a threshold of £20,000/QALY gained, MI SIJF has a probability of being cost-effective versus NSM strategies of 96%, 97%, and 91% for strategies 1, 2, and 3, respectively.
CONCLUSION: MI SIJF appears to be cost-effective over a 5-year time horizon when compared to traditional NSM pathways in an NHS context.
References
- Ann Rheum Dis. 2012 Nov;71(11):1796-802 - PubMed
- Neurosurgery. 2018 Jan 1;82(1):48-55 - PubMed
- Qual Life Res. 2016 Feb;25(2):283-292 - PubMed
- Appl Health Econ Health Policy. 2020 Jun;18(3):363-373 - PubMed
- Pain Physician. 2015 Sep-Oct;18(5):E713-56 - PubMed
- Clinicoecon Outcomes Res. 2015 Dec 18;8:1-14 - PubMed
- Spine (Phila Pa 1976). 2013 Jan 15;38(2):157-68 - PubMed
- Pain. 2000 Jan;84(1):95-103 - PubMed
- JAMA. 2017 Jul 4;318(1):68-81 - PubMed
- Pain Med. 2015 Aug;16(8):1500-18 - PubMed
- Spine (Phila Pa 1976). 2017 Nov 1;42(21):1664-1673 - PubMed
- Pain Med. 2011 May;12(5):732-9 - PubMed
- J Altern Complement Med. 2010 Dec;16(12):1285-90 - PubMed
- Int J Spine Surg. 2015 Mar 05;9:6 - PubMed
- Eur Spine J. 2017 Mar;26(3):708-719 - PubMed
- BMJ Qual Improv Rep. 2017 Feb 10;6(1): - PubMed
- Pain Med. 2012 Mar;13(3):383-98 - PubMed
- Spine J. 2005 Sep-Oct;5(5):520-8; discussion 529 - PubMed
- Pain Med. 2009 Jul-Aug;10(5):850-3 - PubMed
- Clin J Pain. 2016 Nov;32(11):921-926 - PubMed
- Lancet. 2012 Dec 15;380(9859):2197-223 - PubMed
- Pain Physician. 2018 Sep;21(5):489-496 - PubMed
- Clin Orthop Relat Res. 2014 Jun;472(6):1831-8 - PubMed
- Med Devices (Auckl). 2018 Sep 28;11:337-343 - PubMed
- PM R. 2019 Aug;11 Suppl 1:S98-S104 - PubMed
- Pharmacoeconomics. 2007;25(1):3-6 - PubMed
- Medicine (Baltimore). 2018 Feb;97(6):e9809 - PubMed
- Int J Spine Surg. 2016 Aug 23;10:28 - PubMed
- Med Devices (Auckl). 2015 Nov 23;8:485-92 - PubMed
- Ann Surg Innov Res. 2013 Oct 30;7(1):14 - PubMed
- PM R. 2019 Aug;11 Suppl 1:S105-S113 - PubMed
- Expert Rev Neurother. 2013 Jan;13(1):99-116 - PubMed
- Health Technol Assess. 2017 May;21(30):1-184 - PubMed
- Int J Spine Surg. 2015 Jul 22;9:40 - PubMed
- Pain Med. 2011 Apr;12(4):565-70 - PubMed
- Med Devices (Auckl). 2014 Jun 05;7:187-93 - PubMed
- Anesthesiology. 2008 Aug;109(2):279-88 - PubMed
- Med Devices (Auckl). 2019 Sep 26;12:411-422 - PubMed
- Eur Spine J. 2008 Jun;17(6):794-819 - PubMed
- BMJ. 2009 Jun 04;338:b1805 - PubMed
Publication Types